Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 235 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
ORIGINAL ARTICLE
Year : 2014  |  Volume : 18  |  Issue : 3  |  Page : 345-349

Zinc transporter-8 autoantibodies can replace IA-2 autoantibodies as a serological marker for juvenile onset type 1 diabetes in India


1 Department of Endocrinology and Metabolism, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India
2 Department of Endocrinology and Metabolism, M. S. Ramaiah Medical College, Bangalore, Karnataka, India

Date of Web Publication3-May-2014

Correspondence Address:
C Shivaprasad
Department of Endocrinology and Metabolism, Vydehi Institute of Medical Sciences and Research, Bangalore - 560 066, Karnataka
India
Login to access the Email id

Source of Support: UGC, Sri Lanka, Conflict of Interest: None


DOI: 10.4103/2230-8210.131174

Rights and Permissions
   Abstract 

Introduction: Zinc transporter-8 (ZnT8) is an islet cell secretory granule membrane protein recently identified as an autoantigen in type 1 diabetes (T1D). The aim of this study was to estimate the prevalence of antibodies to ZnT8 (ZnT8A) in juvenile onset T1D and to determine the utility of ZnT8A as an independent marker of autoimmunity either alone in antibody-negative subjects or in conjunction with glutamic acid decarboxylase (GAD) and insulinoma-2 antigen antibodies (GADA and IA2A). Research Design: ZnT8A, GADA, and IA2A were measured in sera of consecutive T1D patients (n = 88, age range 2-18 years) within 4 years of diagnosis and 88 sex-matched controls. Results: The prevalences of GADA, ZnT8a, and IA2A were 64.7%, 31.8% and 19.3%, respectively. In newly diagnosed patients, the frequency of ZnT8A was 45%. ZnT8A were positive in 26% of patients negative for both GADA and IA2A. IA2A were positive only in two patients who were negative for other two antibodies. Combined use of ZnT8A and GADA could detect 97% of antibody positive patients. In receiver operating characteristic (ROC) analysis, the performances of GADA and ZnT8As were better than that of IA2A; and AUCs of GADA, ZnT8A, and IA2A for the prediction of T1D were 0.8, 0.65, and 0.59, respectively. Conclusions: ZnT8A complements GADA and increases the diagnostic sensitivity for detection of autoimmunity in juvenile-onset T1D. Inclusion of ZnT8A increases the proportion of patients with antibody positivity to nearly 80%. ZnT8A can replace IA2A as a serological marker for autoimmunity in Indian T1D patients without loss of sensitivity and specificity.

Keywords: Autoantigen, autoimmunity, India, juvenile, type 1 diabetes, zinc transporter


How to cite this article:
Shivaprasad C, Mittal R, Dharmalingam M, Kumar PK. Zinc transporter-8 autoantibodies can replace IA-2 autoantibodies as a serological marker for juvenile onset type 1 diabetes in India. Indian J Endocr Metab 2014;18:345-9

How to cite this URL:
Shivaprasad C, Mittal R, Dharmalingam M, Kumar PK. Zinc transporter-8 autoantibodies can replace IA-2 autoantibodies as a serological marker for juvenile onset type 1 diabetes in India. Indian J Endocr Metab [serial online] 2014 [cited 2019 Sep 19];18:345-9. Available from: http://www.ijem.in/text.asp?2014/18/3/345/131174


   Introduction Top


Zinc transporter-8 (ZnT8) is an islet cell secretory granule membrane protein recently identified as an autoantigen in type 1 diabetes (T1D). [1] Autoantibodies to ZnT8 (ZnT8A) complement the established antibodies to insulin (IAA), GAD (glutamic acid decarboxylase antibodies, GADA), and protein tyrosine phosphatase (insulinoma-2 antigen antibodies, IA2A). Antibodies to ZnT8 have been detected in 60-80% of Caucasian and 33-58% of Asian population with T1D. [2],[3],[4] The combined determination of established diabetes autoantibodies together with the ZnT8A increases the diagnostic sensitivity to over 90% for new onset cases of T1D in Caucasians. A high frequency of patients (45%) with presumed diagnosis of T1D in India lack GADA and IA2A autoantibodies, so establishing the autoimmune basis becomes difficult. [5] A low frequency of IA2A in T1D has been reported from different studies from India. [6],[7] Inclusion of ZnT8A presumably reduces the proportion of patients with negative autoantibodies. As no data on ZnT8A in Indian population are available, the aim of our study was to estimate the prevalence of ZnT8A in T1D patients of Indian origin and determine the utility of ZnT8A as an independent marker of autoimmunity either alone in antibody-negative subjects or in conjunction with GADA and IA2A.


   Materials and Methods Top


Eighty-eight patients who were diagnosed with diabetes before 18 years of age according to American Diabetes Association (ADA) criteria [8] and classified as type 1 diabetic patient on clinical grounds were recruited to the study. Type 1 diabetes (T1D) was defined on the clinical grounds by ketosis at presentation, lean phenotype, requirement for insulin, and/or low C-peptide. The duration of T1D after diagnosis was less than 48 months. Twenty-one of the patients were newly diagnosed cases, and the blood sample was obtained from them within a week after diagnosis. Patients were consecutively recruited from two centers in Bangalore, Bangalore Diabetes Hospital and M S Ramaiah Medical College between 2010 and 2012. Sex-matched healthy nondiabetic controls aged 2-18 years (n = 88) were also recruited. Children with disease duration > 48 months, evidence of secondary diabetes, and those with hormonal abnormalities were excluded. Abdominal X-ray and/or ultrasound were done to rule out pancreatic calcification. Informed consent was obtained from participants and/or parents. Ethical committee approval of the participating hospitals was obtained. ZnT8A, GADA, and IA2As were estimated in both patients and controls. The sera were stored at - 70°C till analysis.

Estimation of autoantibodies

ZnT8, GAD, and IA2 antibodies were estimated using commercial enzyme-linked immunosorbent assay (ELISA) (DLD Diagnotika, GMBH, Germany). ZnT8 autoantibody ELISA kit detects autoantibodies specific to arginine (R) or to tryptophan (W) at residue 325, or to nonspecific variants at residue 325. In ZnT8 antibody ELISA, ZnT8A in test patients' sera, calibrators, and controls were allowed to interact with ZnT8 coated onto ELISA plate wells. After 16 − 20 h incubation, the samples were discarded leaving ZnT8 autoantibodies bound to ZnT8 coated wells. ZnT8 biotin was added in the second incubation step where, through the ability of ZnT8 autoantibodies in the samples to act bivalently (or polyvalently), a bridge would be formed between ZnT8 immobilized on the plate and ZnT8 biotin. Unbound ZnT8 biotin was then removed in a wash step, and the amount of bound ZnT8 biotin determined (in the third incubation step) by addition of streptavidin peroxidase (SA-POD), which bound specifically to biotin. Excess, unbound SA-POD was then washed away and addition of 3,3', 5, 5'-tetramethylbenzidine (TMB) resulted in formation of a blue color. This reaction was stopped by addition of stop solution causing the well contents to turn yellow. The absorbance of the yellow reaction mixture at 405 and 450 nm was then read using an ELISA plate reader. A higher absorbance indicated the presence of ZnT8 autoantibody in the test sample. Low values (less than 50 U/ml) were read off with the 450 nm calibration curve and high values (more than 50 U/ml) were read off with 405 nm calibration curve. The measuring range was 10-2,000 U/ml. A cut-off value of ≥ 15 U/ml was considered as positive. Cut-off values for positive results for GAD and IA2 antibodies were 20 and 7.5 U/ml, respectively based on our laboratory reference norms.

Statistical analysis

Results were expressed as mean ± SD unless otherwise indicated. Autoantibody frequencies and anthropometric and biochemical parameters between patients and controls were compared using the χ2 test, Fisher's exact test, analysis of variance (ANOVA) test, and Student's t-test (two-tailed, independent) where appropriate. Diagnostic performance of three antibody tests was analyzed using receiver operating characteristic (ROC) analysis and pairwise comparison of areas under curves of ROC plots of the autoantibodies were done by a dichotomous, binary classification of the test results as positive or negative. P value less than 0.05 were considered statistically significant.


   Results Top


Comparison of clinical characteristics of patients and controls is presented in [Table 1]. ZnT8A were detected in 31.8% of patients. In newly diagnosed patients, the prevalence of ZnT8A was 45%. The frequencies of GADA and IA2A were 64.7 and 19.3%, respectively. Sixty-eight (77.3%) patients were positive for at least one antibody and five of them were positive for all three antibodies [Figure 1]. ZnT8A were positive in 33.3% of patients positive for GADA and 40% of patients positive for IA2A. ZnT8A were positive in 26% of patients negative for both GADA and IA2A. GADA were positive in 60% of patients negative for other antibodies, whereas IA2 was positive in only two patients negative for other two antibodies.
Figure 1: Venn diagram of frequencies and codetection of autoantibody combinations in in antibody positive patients with T1D

Click here to view
Table 1: Clinical characteristics of patients and controls

Click here to view


ZnT8A and GADA identified 97.7% of antibody positive patients detected by the combined use of all three antibodies. ZnT8A increased the proportion of patients positive for at least one of the antibodies from 64.5 to 75% when compared to GAD alone, from 69 to 77.3% when compared to GADA and IA2A combined. Exclusion of IA2A from the antibody panel reduced antibody positivity by 2.3% only. Five out of 88 controls were positive for antibodies. None of them were positive for more than one antibody and antibody titers were much lower compared to patients.

Diagnostic characteristics of three antibody assays in objectifying autoimmunity in type 1 diabetes are presented in [Table 2]. In ROC analysis, the performances of GADA and ZnT8As were better than that of IA2A, and AUCs of GADA, ZnT8A, and IA2A for the prediction of T1D were 0.8, 0.65 and 0.59 respectively [Table 2] and [Figure 2]. In pair wise comparison of AUCs of ROC curves, AUC of GADA was significantly greater than that of ZnTA and IA2A. AUC of ZnT8A was greater than that of IA2A but didn't reach statistical significance [Table 3].
Figure 2: ROC curve analysis of three autoantibody tests Area under curve (AUC) of GADA-0.647, AUC of ZnT8A-0.32, AUC of IA2A-0.19

Click here to view
Table 2: Diagnostic performance of the antibody tests in receiver operating characteristic analysis

Click here to view
Table 3: Pairwise comparison of receiver operating characteristic curves of three antibody tests

Click here to view



   Discussion Top


The present study shows that ZnT8 antibody is a specific marker of juvenile onset T1D in line with previous studies. ZnT8A were positive in nearly one-third of the patients, and their prevalence was much higher than that of IA2A. In newly diagnosed cases, the prevalence of ZnT8As was 45%. ZnTA were found in one-quarter of T1D subjects classified as autoantibody-negative based on GADA and IA2A.

The frequency of ZnTA in our subjects was much lower compared to that reported among Caucasians. In a study by Wenzlau et al., ZnT8A were detected in 63% of T1D patients at the diagnosis and 2% of healthy controls, and they were positive in 26% of T1D patients who were negative for other islet autoantibodies. [9] In another study involving Swedish children and adolescents with T1D, ZnTA were detected in 65% of subjects. [10] In a Japanese study, ZnT8A frequency was 58% in childhood onset patients and 34% in adult onset T1D patients. [3] The same authors reported ZnT8A prevalences of 58% patients with acute onset and 20% with slow onset type 1 diabetes. [11] In newly diagnosed cases, the prevalence of ZnT8A in our subjects was higher than that reported from China (32.9%). [4] Genetic factors, specifically histocompatibility leukocyte antigen (HLA) haplotypic diversification and SLC30A8 gene polymorphism could be responsible for the differences in frequencies noted among different ethnic populations as shown in previous studies. [10],[12],[13],[14],[15],[16]

A high frequency of type 1B diabetes (45%) has been reported among children and adolescents with recent onset T1D from north India based on negativity for GADA and IA2A. [5] The most significant finding from our study was that the inclusion of ZnT8A increased the antibody detection rate to nearly 80%. This could aid in better classification and risk stratification of early onset diabetes and help differentiating from T1D mimicking forms of diabetes seen in India. In the present study, diagnostic performances of the three assays were compared using ROC analysis. The results from this analysis suggest that ZnT8A is a better diagnostic tool than IA2A for diagnosis of T1D with higher sensitivity, only a slightly lower specificity, but a higher diagnostic accuracy. The combined presence of both the antibodies in serum compared with ZnT8A alone increases the specificity, but contributes little to sensitivity and overall accuracy.

Higher prevalence of type 1B diabetes in India is predominantly due to lower positivity of IA2A antibodies as has been reported from different studies. [6],[7],[17],[18] Our study findings support these earlier reports. Most of the IA2A positive patients in our study were positive for either GADA or ZnT8A and combined use of GADA and ZnT8A could detect > 97% of antibody positive patients detected with the integrated use of all three antibodies, implying that the utility of IA2A was limited and to a large extent redundant. Whereas, inclusion of ZnT8A reduced the proportion of patients with negative autoantibodies, IA2A did not contribute any further in this regard. These findings suggest that ZnT8A have a potential to replace IA2A for screening autoimmunity in Indian T1D patients without loss of sensitivity and specificity. Antibody screening could be done in a cost-effective manner and testing for IA2A reserved for only those patients who are GADA and ZnT8A negative.

Our study has a few limitations. We recruited newly diagnosed T1D patients and those with a shorter duration of diabetes (<4 years) only. The reason for doing this was because ZnT8A titers have been shown to decline exponentially from the clinical onset of T1D with a t1/2 similar to that of C-peptide. [9] We excluded adults with T1D because the frequency of ZnT8A has been shown to be much lower when compared to children and adolescents with T1D. [19],[20] We did not examine the relation of ZnT8A to glycemic control and progression of T1D and the prevalence of ZnT8A in adult onset T1D. Further studies are warranted on the kinetics of post onset decline of ZnT8A and their prevalences in patients with different disease durations. Studies examining how HLA haplotype variation and SLC30A8 gene polymorphism modulate humoral autoreactivity to ZnT8 are also required.

In summary, this is the first study on prevalence of ZnT8 antibodies in juvenile onset T1D from India. Frequency of ZnT8A was higher in newly diagnosed cases. ZnT8A complements GADA and increases the diagnostic sensitivity for detection of autoimmunity in juvenile onset T1D. Inclusion of ZnT8A increases the proportion of patients with antibody positivity to nearly 80%. ZnT8A can replace IA2A as a serological marker for autoimmunity in Indian T1D patients without loss of sensitivity and specificity.

 
   References Top

1.Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-5.  Back to cited text no. 1
    
2.Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 2008;1150:256-9.  Back to cited text no. 2
    
3.Kawasaki E, Nakamura K, Kuriya G, Satoh T, Kobayashi M, Kuwahara H, et al. Differences in the humoral autoreactivity to zinc transporter 8 between childhood-and adult-onset type 1 diabetes in Japanese patients. Clin Immunol 2011;138:146-53.  Back to cited text no. 3
    
4.Yang L, Luo S, Huang G, Peng J, Li X, Yan X, et al. The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese. Diabetes Metab Res Rev 2010;26:579-84.  Back to cited text no. 4
    
5.Balasubramanian K, Dabadghao P, Bhatia V, Colman PG, Gellert SA, Bharadwaj U, et al. High frequency of type 1B (idiopathic) diabetes in North Indian children with recent-onset diabetes. Diabetes Care 2003;26:2697.  Back to cited text no. 5
[PUBMED]    
6.Fida S, Myers M, Mackay IR, Zimmet PZ, Mohan V, Deepa R, et al. Antibodies to diabetes-associated autoantigens in Indian patients with Type 1 diabetes: Prevalence of anti-ICA512/IA2 and anti-SOX13. Diabetes Res Clin Pract 2001;52:205-11.  Back to cited text no. 6
    
7.Goswami R, Kochupillai N, Gupta N, Kukreja A, Lan M, Maclaren NK. Islet cell autoimmunity in youth onset diabetes mellitus in Northern India. Diabetes Res Clin Pract 2001;53:47-54.  Back to cited text no. 7
    
8.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.  Back to cited text no. 8
    
9.Wenzlau JM, Walter M, Gardner TJ, Frisch LM, Yu L, Eisenbarth GS, et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010;95:4712-9.  Back to cited text no. 9
    
10.Delli AJ, Vaziri-Sani F, Lindblad B, Elding-Larsson H, Carlsson A, Forsander G, et al. Better Diabetes Diagnosis Study Group. Zinc transporter 8 autoantibodies and their association with SLC30A8 and HLA-DQ genes differ between immigrant and Swedish patients with newly diagnosed type 1 diabetes in the Better Diabetes Diagnosis study. Diabetes 2012;61:2556-64.  Back to cited text no. 10
    
11.Kawasaki E, Nakamura K, Kuriya G, Satoh T, Kobayashi M, Kuwahara H, et al. Zinc transporter 8 autoantibodies in fulminant, acute-onset, and slow-onset patients with type 1 diabetes. Diabetes Metab Res Rev 2011;27:895-8.  Back to cited text no. 11
    
12.Kawasaki E, Uga M, Nakamura K, Kuriya G, Satoh T, Fujishima K, et al. Association between anti-ZnT8 autoantibody specificities and SLC30A8 Arg325Trp variant in Japanese patients with type 1 diabetes. Diabetologia 2008;51:2299-302.  Back to cited text no. 12
    
13.Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008;57:2693-7.  Back to cited text no. 13
    
14.Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009;52:1881-8.  Back to cited text no. 14
    
15.Brorsson C, Vaziri-Sani F, Bergholdt R, Eising S, Nilsson A, Svensson J, et al. Danish Study Group of Childhood Diabetes. Correlations between islet autoantibody specificity and the SLC30A8 genotype with HLA-DQB1 and metabolic control in new onset type 1 diabetes. Autoimmunity 2011;44:107-14.  Back to cited text no. 15
    
16.Howson JM, Krause S, Stevens H, Smyth DJ, Wenzlau JM, Bonifacio E, et al. Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases. Diabetologia 2012;55:1978-84.  Back to cited text no. 16
    
17.Singh AK, Bhatia E, Dabadghao P, Bhatia V, Gellert SA, Colman PG. Role of islet autoimmunity in the aetiology of different clinical subtypes of diabetes mellitus in young north Indians. Diabet Med 2000;17:275-80.  Back to cited text no. 17
    
18.Tandon N, Shtauvere-Brameus A, Hagopian WA, Sanjeevi CB. Prevalence of ICA-12 and other autoantibodies in north Indian patients with early-onset diabetes. Ann N Y Acad Sci 2002;958:214-7.  Back to cited text no. 18
    
19.Kawasaki E, Nakamura K, Kuriya G, Satoh T, Kuwahara H, Kobayashi M, et al. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. J Clin Endocrinol Metab 2010;95:707-13.  Back to cited text no. 19
    
20.Andersen MK, Härkönen T, Forsblom C, Groop PH, Knip M, Tuomi T. Zinc transporter type 8 autoantibodies (ZnT8A): Prevalence and phenotypic associations in latent autoimmune diabetes patients and patients with adult onset type 1 diabetes. Autoimmunity 2013;46:251-8.  Back to cited text no. 20
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]


This article has been cited by
1 Clinical features, biochemistry and HLA-DRB1 status in youth-onset type 1 diabetes in Pakistan
Asher Fawwad,Denira Govender,Mohammad Yakoob Ahmedani,Abdul Basit,Julie Ann Lane,Steven John Mack,Mark Alvin Atkinson,Clive Henry Wasserfall,Graham David Ogle,Janelle Annette Noble
Diabetes Research and Clinical Practice. 2019;
[Pubmed] | [DOI]
2 Could ZnT8 antibodies replace ICA, GAD, IA2 and insulin antibodies in the diagnosis of type 1 diabetes?
A. Lounici Boudiaf,D. Bouziane,M. Smara,Y. Meddour,E.M. Haffaf,B. Oudjit,S. Chaib Mamouzi,S. Aouichat Bouguerra
Current Research in Translational Medicine. 2018;
[Pubmed] | [DOI]
3 Zinc transporter 8 autoantibody (ZnT8A) by ELISA for diagnosing type 1 diabetes among Chinese people
Xuan Qiu,Cuili Ning,Lin Xiao,Jianmin Jing,Zhenyun Mu,Kuanzhi Liu
International Journal of Diabetes in Developing Countries. 2018;
[Pubmed] | [DOI]
4 Screening of ZnT8 autoantibodies in the diagnosis of autoimmune diabetes in a large French cohort
Lorna Garnier,Lucien Marchand,Marine Benoit,Marc Nicolino,Nathalie Bendelac,Catherine Wright,Philippe Moulin,Christine Lombard,Charles Thivolet,Nicole Fabien
Clinica Chimica Acta. 2018; 478: 162
[Pubmed] | [DOI]
5 Prevalence of islet autoantibodies in Thai juvenile-onset type 1 diabetes
Chayanis Trisorus,Suphab Aroonparkmongkol,Hataichanok Bansiddhi Kongmanas,Taninee Sahakitrungruang
Pediatrics International. 2018; 60(11): 1002
[Pubmed] | [DOI]
6 Zinc Transporter 8 Autoantibodies Assessment in Daily Practice
Hala Hussein,Fidaa Ibrahim,Eugène Sobngwi,Jean François Gautier,Philippe Boudou
Clinical Biochemistry. 2016;
[Pubmed] | [DOI]
7 Anti-zinc transporter protein 8 autoantibodies significantly improve the diagnostic approach to type 1 diabetes: an Italian multicentre study on paediatric patients
Martina Fabris,Silvia Zago,Marco Liguori,Maria Teresa Trevisan,Manuela Zanatta,Alberto Comici,Giorgio Zanette,Eva Carlin,Francesco Curcio,Elio Tonutti
Autoimmunity Highlights. 2015; 6(1-2): 17
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed1431    
    Printed16    
    Emailed0    
    PDF Downloaded351    
    Comments [Add]    
    Cited by others 7    

Recommend this journal